Results from two vaccine cohort event monitoring studies on Influenza vaccines and COVID-19 vaccines
Pharmacovigilance centre Lareb has published results from two vaccine cohort event monitoring studies (CEM) on Influenza vaccines and COVID-19 vaccines. The results from the CEM on Influenza vaccination show that females experience adverse events following immunization (AEFIs) more often than males. The CEM on COVID-19 vaccines show that the odds of reporting an AEFI is significantly higher in the presence of some comorbidities.
CEM on Influenza Vaccines
The effect of sex on the incidence, latency, duration and perceived burden of adverse events following seasonal influenza vaccination in the Netherlands was investigated. Data from CEM studies were assessed, which were performed over nine consecutive years (2013–2021), each covering several months during the seasonal influenza campaign in the Netherlands. The cohort included 7789 participants (53.0% females). Females had around 2.5-fold (p < 0.001) higher odds of developing any AEFI compared with males. Additionally, this study shows that the course of AEFIs only partially differs between the sexes.
CEM on COVID-19 Vaccines
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands was assessed. The results showed that the odds of reporting an AEFI after COVID-19 vaccination is significantly higher in the presence of some comorbidities, including psychological disorders and endocrine disorders. In-depth research is needed to validate our results and unravel the observed associations from a mechanistic perspective.